In the last trading session, 4.21 million ReShape Lifesciences Inc (NASDAQ:RSLS) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $1.36 changed hands at $0.24 or 21.43% during last session, the market valuation stood at $1.00M. RSLS’s last price was a discount, traded about -2032.35% off its 52-week high of $29.00. The share price had its 52-week low at $1.01, which suggests the last value was 25.74% up since then.

Analysts gave the ReShape Lifesciences Inc (RSLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RSLS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ReShape Lifesciences Inc’s EPS for the current quarter is expected to be 0.

ReShape Lifesciences Inc (NASDAQ:RSLS) trade information

Instantly RSLS was in green as seen at the end of in last trading. With action -41.63%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -69.51%, with the 5-day performance at -41.63% in the red. However, in the 30-day time frame, ReShape Lifesciences Inc (NASDAQ:RSLS) is -69.51% down.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 76.96%.

RSLS Dividends

ReShape Lifesciences Inc is expected to release its next quarterly earnings report in March.

Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 2.42 shares estimated at $3288.0 under it, the former controlled 0.33% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.12% of the shares, roughly 860.0 shares worth around $1169.0.